CompletedNCT01082588
Pravastatin and cholesterol, inflammation and cognition in schizophrenia
About this title
Read the official source — NCT01082588Medication studyAges 18–68United States
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 68 years. Other eligibility criteria applied.
- Listed locations
- BostonSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateJune 2010
- Recruitment status
- Completed
- Enrollment listed in the registry
- 60
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 68 Years
- Official registry ID
- NCT01082588
- Official title
Show the full official title
Phase 4 Study of the Effects of Pravastatin on Cholesterol Levels, Inflammation and Cognition in Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Pravastatin and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 68 years. Other eligibility criteria applied.
